Regulatory insights for healthcare innovation.

Despite thorough engagement with agencies such as the FDA, companies continue to face CMC and analytical issues that lead to Complete Response Letters. These issues often arise late, exposing gaps between sponsor expectations and FDA standards, especially in assay reproducibility, validation, and tech transfer.

AI is reshaping medical devices, but regulatory hurdles remain. Validation is vital for FDA approval, especially with the complexities of machine learning. This article outlines key requirements including data quality, performance testing, clinical validation, transparency, risk management, lifecycle management, and real-world monitoring.

As medical devices evolve into software-driven, connected systems, software remediation has become a critical driver of patient safety, regulatory compliance, and commercial success. Yet current frameworks remain fragmented, reactive, and poorly integrated, creating systemic risk and a major opportunity to build regulatory-aware software infrastructure.

A medical device may be engineered to a single design specification and validated to the same performance standards globally, but its regulatory pathway varies significantly depending on the market in which it is placed.

At E&E Medicals, we are excited to introduce eeMeds™, an AI-powered preventative wellness platform designed to unify fragmented lifestyle apps into a single adaptive personalization engine focused on sleep, stress, weight trends, movement, and behavioral optimization.

A Predetermined Change Control Plan (PCCP) is not regulatory flexibility. It is a pre-authorized change under strict control. This article explains why PCCPs require clear change definitions, statistical thresholds, bias monitoring, drift detection, rollback procedures, and documented impact assessments.

The European Commission has proposed a targeted revision of the Medical Device Regulation and In Vitro Diagnostic Regulation aimed at supporting innovation while reducing unnecessary administrative burden. This article explores the impact on technical documentation, manufacturers, implementation challenges, and software oversight.

The EU Artificial Intelligence Act introduces significant new obligations for digital health and Software as a Medical Device developers. This article explains how high-risk AI classification, data governance, human oversight, transparency, cybersecurity, and post-market monitoring intersect with EU MDR requirements.

FDA’s revised digital health guidance expands exemptions for certain low-risk digital health products from active regulatory oversight. This article explains how wearables, wellness products, clinical decision support tools, and AI-enabled software may be affected by the updated risk-based approach.

The revised ISO 10993-1 marks a significant shift in biocompatibility assessment by enabling risk-based justifications supported by real-world evidence. This article explores pre-market submissions, manufacturer implications, AI-enabled device challenges, and regulatory pitfalls.

The U.S. Food and Drug Administration has updated its Real-World Evidence policies to allow greater use of large, well-curated data sources in medical device marketing submissions. This article explains how RWE may support safety and effectiveness for AI-enabled medical devices.

On January 6, 2025, the FDA released draft guidance on development, lifecycle management, and marketing submissions for AI-enabled device software. This article explains key lifecycle expectations, submission considerations, manufacturer implications, and regulatory pitfalls.

This draft guidance describes a streamlined process for FDA reviewers to evaluate a manufacturer's QMS during premarket review, replacing the disconnected, siloed approach with a proactive use of QMS information to achieve a smoother and more effective review.

The FDA provides several guidance documents for Chemistry, Manufacturing, and Controls submissions, including post-approval manufacturing changes, comparability protocols, disposable manufacturing materials, nanomaterials, and current good manufacturing practice requirements for combination products.

Cybersecurity documentation is vital for PMA submissions to the FDA, ensuring device safety and effectiveness. This article outlines cybersecurity risk assessment, security controls, SBOM, vulnerability disclosure, incident response planning, labeling, monitoring, and documentation requirements.

The FDA advocates adopting cloud-based systems for medical devices, highlighting benefits such as scalability, enhanced security, collaboration, innovation potential, and operational cost savings. This article explains FDA perspectives and best practices for cloud-based medical device systems.

Regulatory agencies worldwide are encountering significant obstacles in managing and supervising AI-enabled medical devices. This article explores AI/ML regulatory oversight, ethical concerns, bias, performance degradation, transparency, cross-site deployment, post-market surveillance, cybersecurity risks, and standardized validation.